Global Wellness Strategies Closes First Tranche of Non-Brokered Private Placement
Global Wellness Strategies Closes First Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X4) (OTCQB: GWSFF) ("Global" or the "Company") is pleased to announce the first tranche closing of its non-brokered private placement (the "Offering") for gross proceeds of $588,500.
温哥華,不列顛哥倫比亞省-(Newsfile Corp.-2022年2月22日)全球健康戰略公司(CSE:GWS)(FSE:O3X4)(OTCQB:GWSFF)(“全球”或“公司”)很高興宣佈其非經紀私募(“發售”)的第一批結束,總收益為588,500美元。
The securities sold pursuant to the Offering consist of 2,977,779 units of the Issuer ("Units") at a price of CAD$0.18 per unit. Each Unit consists of one common share and one common share purchase warrant. Each whole warrant will entitle the holder to purchase, for a period of 3 years from the date of issue, one additional common share of the Issuer at an exercise price of CAD $0.30 per common share. The warrants are subject to an acceleration provision in favour of the Company in the event that the Shares trade on a recognized exchange at more than $0.45 for a 14 day period, which can include days where no shares trade. No finder's fees were paid in connection with the placement. In addition, the Company will also issue 291,667 common shares for the settlement of current debts incurred to a consultant of the Company representing a total of $52,500. The Company will continue with the placement for an aggregate total of up to $3 million.
根據發售出售的證券包括2,977,779個發行人單位(“單位”),每單位價格為0.18加元。每個單位由一股普通股和一股普通股認購權證組成。每份完整的認股權證將使持有者有權在自發行之日起的3年內,以每股普通股0.30加元的行使價購買發行人額外的一股普通股。如果認股權證在公認的交易所以超過0.45美元的價格交易,14天內(其中可能包括沒有股票交易的天數),認股權證將受到有利於公司的加速條款的約束。沒有支付與配售相關的尋人費用。此外,公司還將發行291,667股普通股,用於清償目前欠公司顧問的債務,總額為52,500美元。該公司將繼續進行配售,總金額高達300萬美元。
The use of proceeds from this raise are to further the 100% acquisition of Cannvalate Pty Ltd subsidiary Shanti Therapeutics Pty Ltd based in Australia and their commencement of proof of-concept clinical trial submissions, plus non-clinical studies for opening an IND (Investigational New Drug) File with the FDA. Funds will also be used for the establishment of a psychedelic prescribing clinic plus help to compensate the scientific executive team and for general and administrative expenses of Global Wellness Strategies Inc.
此次募集所得將用於進一步100%收購設在澳大利亞的Cannvalate Pty Ltd子公司Shanti Treateutics Pty Ltd,並開始提交概念驗證臨牀試驗,以及向FDA提交IND(調查新藥)文件的非臨牀研究。資金還將用於建立迷幻處方診所,並幫助支付科學執行團隊的薪酬,以及全球健康戰略公司的一般和行政費用。
About Shanti Therapeutics
山蒂治療公司簡介
Shanti Therapeutics is a first-in-class biotech utilizing the neuromodulation properties of MDMA (aka Ecstasy) to pre-emptively treat preoperative pain. Shanti has commenced a path to their clinical trial in 22 healthy volunteers comparing the pain tolerance threshold in patients who have had exposure to a proprietary dose and formulation of MDMA. This proof-of-concept clinical study is to gauge the effect size of an increase in the pain threshold in subjects who have been pre-emptively treated with MDMA.
Shanti治療公司是一家一流的生物技術公司,利用MDMA(又名搖頭丸)的神經調節特性先發制人地治療術前疼痛。Shanti已經開始在22名健康志願者身上進行臨牀試驗,比較了接觸過專有劑量和MDMA配方的患者的疼痛耐受閾值。這項概念驗證臨牀研究旨在評估預先接受MDMA治療的受試者痛閾升高的影響大小。
About Global Wellness Strategies
關於全球健康戰略
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.
Global Wellness Strategy是一個潛在的推動者,在快速增長的健康消費品市場為高增長的公司提供財務、運營和管理方面的幫助。該公司的重點是全球保健、迷幻藥、真菌學、大麻和CBD,這些都是與醫療保健相關的目標公司。
For further information visit websites:
欲瞭解更多信息,請訪問以下網站:
and
和
Or Contact Meris Kott CEO 604.484.0355 or email to info@globalwellnessstrategies.com
或聯繫Meris Kott首席執行官604.484.0355,或發送電子郵件至info@globalwell nessstrategies.com
Further information about the Company is available on under the Company's profile.
欲瞭解更多有關該公司的信息,請訪問公司簡介。
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation.
加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。本新聞稿中包含的某些陳述可能構成“前瞻性陳述”或“前瞻性信息”(統稱為“前瞻性信息”),因為這些術語在私人證券訴訟中使用。
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問